Diabetic Macular Edema

New findings observing links between visual acuity, disease progression and risk loci could inform new clinical studies of the leading cause of irreversible vision loss.

Monthly IV pegcetacoplan was associated with 39% reduced risk of progression from incomplete to complete RPE and outer retinal atrophy.

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

YOSEMITE and RHINE data further supports the novel agent for diabetic macular edema. A study investigators explains the impact of the new findings.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.

Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.

Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.

The Director of Retina Services at Wills Eye Hospital joins to discuss the historic FDA approval granted for a novel method of ophthalmic care: a permanent implant that allows for vision-saving formula therapy to treat the eye continually.

Key opinion leaders review the efficacy and safety of available VEGF inhibitors for the treatment of macular edema and explain how effectiveness is evaluated.

Experts in retinal diseases provide insight into when to prescribe VEGF inhibitors and the initial conversations with patients about treatment.

Proportion of eyes with IOP-related events supported monitoring in eyes treated with anti-VEGF therapy for macular edema associated with CRVO or HRVO for up to 60 months.

Phase 3 data show the solution works as fast 15 minutes and lasts for up to 6 hours, to improve near vision without impacting distance vision.

Triamcinolone acetonide injectable suspension has been approved for administration via the suprachoroidal pathway—located in the back of the eye.

A new cross-sectional analysis from ASRS 2021 show White patients are generally overrepresented in randomized, controlled trials for DME.

According to 3x3 mm and 6x6 mm OCTA scans, there were no significant changes in mean macular intercapillary area measures for all tested regions.

Data presented at ADA 2021 supports the noninferiority of faricimab to aflibercept.